Health
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2024-10-29 07:57
1536
Asia CEO Awards Adds USANA Philippines to Their Circle of Excellence
MANILA, Philippines, Oct. 29, 2024 /PRNewswire/ -- USANA Health Sciences, Inc. and itsPhilippines market were recently added to the illustrious Circle of Excellence from the Asia CEO Awards. The Circle of Excellence recognizes the top companies inthe Philippines that have shown success and value ...
2024-10-29 07:47
1200
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while d...
2024-10-29 06:32
1394
KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I
Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 28, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to...
2024-10-29 05:42
990
Alimetry revolutionises gut health diagnosis by integrating AI into its wearable device, raises US $18m to fuel next phase of growth
MINNEAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Alimetry
2024-10-29 05:08
1107
$3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT
CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY
TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION
BOULDER, Colo. , Oct. 28, 2024 /PRNewswire/ -- Tessara Therapeutics
2024-10-29 02:00
1449
Ping An Health Collaborates with Industry to Launch China's First "Internet-Based Family Doctor Service Standards"
HONG KONG and SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently participated in the finalization meeting for the "High-Quality Development Standards for Internet-Based...
2024-10-28 21:30
2088
TeleVox Applauded by Frost & Sullivan for Improving Patient Experience through Effective Engagement and Customer Value
TeleVox's highly flexible platform provides PRM capabilities covering the full extent of healthcare stakeholders, enhancing the patient population experience, decreasing missed appointments, and facilitating better care outcomes. SAN ANTONIO, Oct. 28, 2024 /PRNewswire/ -- Frost & Sullivan recentl...
2024-10-28 21:00
1211
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
* Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year * Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-over-Year * Net Profit Attributable to the Owners o...
2024-10-28 19:03
1869
I-Mab to Participate at the Truist Securities BioPharma Symposium
ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meet...
2024-10-28 19:00
904
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expressio...
2024-10-28 17:00
1010
Lilly's Mounjaro® (tirzepatide) Approved in Hong Kong in KwikPen® Presentation for Chronic Weight Management and Type 2 Diabetes, Offering a New Option for the Treatment of Obesity, Overweight and Type 2 Diabetes
* Adults taking Mounjaro in a clinical trial lost on average 48 lb. at the highest dose1,2 * Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials6-12 * Mounjaro represents a new class of obesity and diabetes medicines and is expected to be ava...
2024-10-28 15:12
1410
/C O R R E C T I O N -- Seegene Inc./
In the news release, Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative, issued 24-Oct-2024 by Seegene Inc. over PR Newswire, we are advised by the company that the second photo and its caption should be removed as origina...
2024-10-28 12:50
3695
DKSH and FrontierView Publish Whitepaper on Southeast Asia as a Growth Accelerator for Global Healthcare Firms
DKSH and FrontierView, a business intelligence and advisory firm, published a whitepaper providing an in-depth assessment of the healthcare status of the Southeast Asia (SEA) region. The research collated in DKSH's whitepaper provides a comprehensive analysis of the regional healthcare landscape,...
2024-10-28 09:00
4139
PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint
PROVISION Study demonstrates significant economic and resource utilization advantages in FFRangio cohort compared to invasive wire-based FFR cohort WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Today at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) c...
2024-10-28 02:56
1242
RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has cleared its IND application for th...
2024-10-26 01:24
3913
KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)
SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Fo...
2024-10-26 00:33
1676
Lifezoom Unveils Next-Gen 3-in-1 Handheld Red Light Therapy Wand - Transform Your Skincare Routine
NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Lifezoom, a new force in red light therapy with strong R&D capabilities, is about to launch its handheld red light therapy wand, its newest device, as a declaration of its high-end brand route and also shows its determination of providing users with safer a...
2024-10-25 21:00
1056
WOORIEN launches 'MyVet CT Plus': Advanced Veterinary imaging Solution
* Lowering CT barriers and improving diagnostic quality * Spiral-Linear Technology with Enhanced Power * Various and Wide FOV with Reduced Scan Time HWASEONG, South Korea, Oct. 25, 2024 /PRNewswire/ -- WOORIEN Co., Ltd, a company specializing in veterinary imaging equipment and solutions, pr...
2024-10-25 21:00
2434
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...
2024-10-25 20:30
1816
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 303 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8683
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5536
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5116
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4753
